Acute renal failure after nonmyeloablative hematopoietic cell transplantation

Chirag Parikh, Brenda M. Sandmaier, Rainer F. Storb, Karl G. Blume, Firoozeh Sahebi, David G. Maloney, Michael B. Maris, Yago Nieto, Charles L. Edelstein, Robert W. Schrier, Peter Mcsweeney

Research output: Contribution to journalArticle

Abstract

Acute renal failure (ARF) is a common life-threatening complication after myeloablative allogeneic hematopoietic cell transplantation (HCT). Nonmyeloablative HCT aims to eradicate the malignancy with graft-versus-tumor effect, rather than with high doses of chemoradiotherapy. It may be anticipated that a lower risk of ARF exists in nonmyeloablative HCT as a result of the milder preconditioning regimen. However, the patients who receive the nonmyeloablative HCT are older individuals who are not eligible for the more toxic allogeneic myeloablative procedure. The goal of this study was to evaluate ARF in a large group of patients who received nonmyeloablative HCT. This cohort study enrolled patients who were undergoing nonmyeloablative HCT at four major centers from 1998 to 2001. Conditioning therapy involved total body irradiation 2 Gy ± fludarabine 30 mg/m2. Posttransplantation immunosuppression consisted of cyclosporine or tacrolimus and mycophenolate mofetil. ARF was classified into four grades, similar to previous studies in the literature. Collectively, 253 patients were recruited into this study. ARF (>50% decrease in GFR) occurred in 40.4% of patients over a 3-mo period, with 4.4% of patients requiring dialysis. The overall mortality in the study population was 34% at 1 yr. The mortality increased with worsening grade of ARF. The combined need for dialysis and artificial ventilation was associated with a mortality exceeding 80%. Although the number of patients who develop ARF is significant, the risk of developing ARF that requires dialysis after nonmyeloablative HCT is infrequent despite the older age of the patients. The data are also suggestive that ARF may contribute to mortality after nonmyeloablative HCT.

Original languageEnglish (US)
Pages (from-to)1868-1876
Number of pages9
JournalJournal of the American Society of Nephrology
Volume15
Issue number7
DOIs
StatePublished - Jul 1 2004
Externally publishedYes

Fingerprint

Cell Transplantation
Acute Kidney Injury
Dialysis
Mortality
Mycophenolic Acid
Behavior Therapy
Whole-Body Irradiation
Poisons
Chemoradiotherapy
Tacrolimus
Immunosuppression
Cyclosporine
Neoplasms
Cohort Studies
Transplants

ASJC Scopus subject areas

  • Nephrology

Cite this

Parikh, C., Sandmaier, B. M., Storb, R. F., Blume, K. G., Sahebi, F., Maloney, D. G., ... Mcsweeney, P. (2004). Acute renal failure after nonmyeloablative hematopoietic cell transplantation. Journal of the American Society of Nephrology, 15(7), 1868-1876. https://doi.org/10.1097/01.ASN.0000129981.50357.1C

Acute renal failure after nonmyeloablative hematopoietic cell transplantation. / Parikh, Chirag; Sandmaier, Brenda M.; Storb, Rainer F.; Blume, Karl G.; Sahebi, Firoozeh; Maloney, David G.; Maris, Michael B.; Nieto, Yago; Edelstein, Charles L.; Schrier, Robert W.; Mcsweeney, Peter.

In: Journal of the American Society of Nephrology, Vol. 15, No. 7, 01.07.2004, p. 1868-1876.

Research output: Contribution to journalArticle

Parikh, C, Sandmaier, BM, Storb, RF, Blume, KG, Sahebi, F, Maloney, DG, Maris, MB, Nieto, Y, Edelstein, CL, Schrier, RW & Mcsweeney, P 2004, 'Acute renal failure after nonmyeloablative hematopoietic cell transplantation', Journal of the American Society of Nephrology, vol. 15, no. 7, pp. 1868-1876. https://doi.org/10.1097/01.ASN.0000129981.50357.1C
Parikh, Chirag ; Sandmaier, Brenda M. ; Storb, Rainer F. ; Blume, Karl G. ; Sahebi, Firoozeh ; Maloney, David G. ; Maris, Michael B. ; Nieto, Yago ; Edelstein, Charles L. ; Schrier, Robert W. ; Mcsweeney, Peter. / Acute renal failure after nonmyeloablative hematopoietic cell transplantation. In: Journal of the American Society of Nephrology. 2004 ; Vol. 15, No. 7. pp. 1868-1876.
@article{0de38fc6f6274936a82588f697390ece,
title = "Acute renal failure after nonmyeloablative hematopoietic cell transplantation",
abstract = "Acute renal failure (ARF) is a common life-threatening complication after myeloablative allogeneic hematopoietic cell transplantation (HCT). Nonmyeloablative HCT aims to eradicate the malignancy with graft-versus-tumor effect, rather than with high doses of chemoradiotherapy. It may be anticipated that a lower risk of ARF exists in nonmyeloablative HCT as a result of the milder preconditioning regimen. However, the patients who receive the nonmyeloablative HCT are older individuals who are not eligible for the more toxic allogeneic myeloablative procedure. The goal of this study was to evaluate ARF in a large group of patients who received nonmyeloablative HCT. This cohort study enrolled patients who were undergoing nonmyeloablative HCT at four major centers from 1998 to 2001. Conditioning therapy involved total body irradiation 2 Gy ± fludarabine 30 mg/m2. Posttransplantation immunosuppression consisted of cyclosporine or tacrolimus and mycophenolate mofetil. ARF was classified into four grades, similar to previous studies in the literature. Collectively, 253 patients were recruited into this study. ARF (>50{\%} decrease in GFR) occurred in 40.4{\%} of patients over a 3-mo period, with 4.4{\%} of patients requiring dialysis. The overall mortality in the study population was 34{\%} at 1 yr. The mortality increased with worsening grade of ARF. The combined need for dialysis and artificial ventilation was associated with a mortality exceeding 80{\%}. Although the number of patients who develop ARF is significant, the risk of developing ARF that requires dialysis after nonmyeloablative HCT is infrequent despite the older age of the patients. The data are also suggestive that ARF may contribute to mortality after nonmyeloablative HCT.",
author = "Chirag Parikh and Sandmaier, {Brenda M.} and Storb, {Rainer F.} and Blume, {Karl G.} and Firoozeh Sahebi and Maloney, {David G.} and Maris, {Michael B.} and Yago Nieto and Edelstein, {Charles L.} and Schrier, {Robert W.} and Peter Mcsweeney",
year = "2004",
month = "7",
day = "1",
doi = "10.1097/01.ASN.0000129981.50357.1C",
language = "English (US)",
volume = "15",
pages = "1868--1876",
journal = "Journal of the American Society of Nephrology : JASN",
issn = "1046-6673",
publisher = "American Society of Nephrology",
number = "7",

}

TY - JOUR

T1 - Acute renal failure after nonmyeloablative hematopoietic cell transplantation

AU - Parikh, Chirag

AU - Sandmaier, Brenda M.

AU - Storb, Rainer F.

AU - Blume, Karl G.

AU - Sahebi, Firoozeh

AU - Maloney, David G.

AU - Maris, Michael B.

AU - Nieto, Yago

AU - Edelstein, Charles L.

AU - Schrier, Robert W.

AU - Mcsweeney, Peter

PY - 2004/7/1

Y1 - 2004/7/1

N2 - Acute renal failure (ARF) is a common life-threatening complication after myeloablative allogeneic hematopoietic cell transplantation (HCT). Nonmyeloablative HCT aims to eradicate the malignancy with graft-versus-tumor effect, rather than with high doses of chemoradiotherapy. It may be anticipated that a lower risk of ARF exists in nonmyeloablative HCT as a result of the milder preconditioning regimen. However, the patients who receive the nonmyeloablative HCT are older individuals who are not eligible for the more toxic allogeneic myeloablative procedure. The goal of this study was to evaluate ARF in a large group of patients who received nonmyeloablative HCT. This cohort study enrolled patients who were undergoing nonmyeloablative HCT at four major centers from 1998 to 2001. Conditioning therapy involved total body irradiation 2 Gy ± fludarabine 30 mg/m2. Posttransplantation immunosuppression consisted of cyclosporine or tacrolimus and mycophenolate mofetil. ARF was classified into four grades, similar to previous studies in the literature. Collectively, 253 patients were recruited into this study. ARF (>50% decrease in GFR) occurred in 40.4% of patients over a 3-mo period, with 4.4% of patients requiring dialysis. The overall mortality in the study population was 34% at 1 yr. The mortality increased with worsening grade of ARF. The combined need for dialysis and artificial ventilation was associated with a mortality exceeding 80%. Although the number of patients who develop ARF is significant, the risk of developing ARF that requires dialysis after nonmyeloablative HCT is infrequent despite the older age of the patients. The data are also suggestive that ARF may contribute to mortality after nonmyeloablative HCT.

AB - Acute renal failure (ARF) is a common life-threatening complication after myeloablative allogeneic hematopoietic cell transplantation (HCT). Nonmyeloablative HCT aims to eradicate the malignancy with graft-versus-tumor effect, rather than with high doses of chemoradiotherapy. It may be anticipated that a lower risk of ARF exists in nonmyeloablative HCT as a result of the milder preconditioning regimen. However, the patients who receive the nonmyeloablative HCT are older individuals who are not eligible for the more toxic allogeneic myeloablative procedure. The goal of this study was to evaluate ARF in a large group of patients who received nonmyeloablative HCT. This cohort study enrolled patients who were undergoing nonmyeloablative HCT at four major centers from 1998 to 2001. Conditioning therapy involved total body irradiation 2 Gy ± fludarabine 30 mg/m2. Posttransplantation immunosuppression consisted of cyclosporine or tacrolimus and mycophenolate mofetil. ARF was classified into four grades, similar to previous studies in the literature. Collectively, 253 patients were recruited into this study. ARF (>50% decrease in GFR) occurred in 40.4% of patients over a 3-mo period, with 4.4% of patients requiring dialysis. The overall mortality in the study population was 34% at 1 yr. The mortality increased with worsening grade of ARF. The combined need for dialysis and artificial ventilation was associated with a mortality exceeding 80%. Although the number of patients who develop ARF is significant, the risk of developing ARF that requires dialysis after nonmyeloablative HCT is infrequent despite the older age of the patients. The data are also suggestive that ARF may contribute to mortality after nonmyeloablative HCT.

UR - http://www.scopus.com/inward/record.url?scp=19244365765&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=19244365765&partnerID=8YFLogxK

U2 - 10.1097/01.ASN.0000129981.50357.1C

DO - 10.1097/01.ASN.0000129981.50357.1C

M3 - Article

C2 - 15213275

AN - SCOPUS:19244365765

VL - 15

SP - 1868

EP - 1876

JO - Journal of the American Society of Nephrology : JASN

JF - Journal of the American Society of Nephrology : JASN

SN - 1046-6673

IS - 7

ER -